Chemesis International Inc. (CSE:CSI, OTC:CADMF, FRA:CWAA) (the “Company” or “Chemesis”), announces the addition of Chief Science Officer, Dr. Joshua Hartsel, a leader in the Research and Development of cannabis and hemp extraction technologies across the industry.
Dr. Hartsel’s experience in the cannabis industry has a special focus on extraction and finished goods manufacturing. His experience working with both THC & CBD on a commercial scale and building several startups offers significant value to the team. Chemesis is primarily focused on ensuring product consistency and quality, with his guidance, the company will exceed those objectives.
Dr. Hartsel earned his Ph.D. from Virginia Polytechnic Institute and State University in Medicinal Organic Chemistry, and received his Bachelor’s of Science in Chemistry from Radford University. Continuing his graduate studies on malaria insecticides with the Bill and Melinda Gates Foundation, Dr. Hartsel also spent several years at the University of California, Irvine as a postdoctoral fellow in the Public Health Department.
Dr. Hartsel previous working experience in the cannabis industry includes:
- Chief Executive Officer of Delta-9 Technologies, where he leads the company’s successful development of industrial-scale automated hydrocarbon extractors.
- Chief Executive Officer of Blue Sky Technologies, where he develops industrial scale extraction of cannabidiol (CBD) and rare non-psychoactive cannabinoid and supplements.
- Chief Science Officer at Ananda Hemp, where Dr. Hartsel designed and managed the build of a commercial scale extraction laboratory.
- In addition, Dr. Hartsel has worked as the Director of R&D for Privateer Holdings and CV Sciences, where he assisted in the development and strategic investments into cannabis products.
“Chemesis has assembled an asset portfolio that I believe my expertise can be leveraged,” said Dr. Joshua Hartsel. “I look forward to working together with the Chemesis’ team and the extraction facilities to further add efficiencies and increase the Company’s capabilities.”
“The addition of Dr. Hartsel brings a wealth of hands on experience in commercial scale extraction but also relationships that will allow the Company to continue to grow our extraction services,” said CEO of Chemesis, Edgar Montero. “His education and experience will allow Chemesis to continue to delivery high quality products and excel in its manufacturing capabilities.”
On Behalf of The Board of Directors
CEO and Director
About Chemesis International Inc.
Chemesis International Inc. is a vertically integrated U.S. Multi-State operator with International operations in Puerto Rico, and Colombia.
The Company focuses on prudent capital allocation to ensure it maintains a first mover advantage as it enters new markets and is committed to differentiate itself by deploying resources in markets with major opportunities. The Company operates a portfolio of brands which cater to a wide community of cannabis consumers, with focus on quality and consistency.
Chemesis has facilities in both Puerto Rico and California, and is in the process of constructing a GMP certified facility in Colombia. Chemesis’ Puerto Rico operations are licensed to operate 100,000 ft2 of cultivation, and 35,000 ft2 of manufacturing floor space. The Company is positioned to win additional licenses in highly competitive merit-based US states, and will expand its footprint to ensure it maintains a first mover advantage.
1 (604) 398-3378
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business, its product offerings and plans for sales and marketing, including finalizing an acquisition in Colombia. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).